FOLFIRINOX Improves PFS Compared with Gemcitabine in Patients with Locally Advanced Pancreatic Carcinoma By Ogkologos - May 26, 2025 573 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PRODIGE 29-UCGI 26 (NEOPAN) study Source RELATED ARTICLESMORE FROM AUTHOR Mezigdomide-Carfilzomib-Dexamethasone Prolongs PFS Compared with Carfilzomib-Dexamethasone at First Relapse in Patients with Relapsed Or Refractory Multiple Myeloma FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder Cancer Systemic Aging Associated with a Higher Risk of Early-Onset Solid Cancers MOST POPULAR Breast Cancer Survivor Uses Comedy to Spread Awareness and Address Disparities October 22, 2021 Outcome of EMA Assessment on Use of Lutetium (177Lu) in Treatment... October 15, 2025 EMA Recommends Extension of Therapeutic Indications for Tislelizumab June 7, 2024 Tattoo Artist Offers Free Nipple Tattoos To Breast Cancer Patients That... March 19, 2020 Load more HOT NEWS Adagrasib Shows Clinical Efficacy in Patients with Previously Treated KRASG12C-Mutated Advanced... 3…2…1…Countdown to Medicare Open Enrollment Coronavirus y COVID-19: Qué deben saber las personas con cáncer FDA Approves Elacestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast...
